Article Text

other Versions

Impact of Late Incomplete Stent Apposition After Sirolimus-Eluting Stent Implantation on 4-Year Clinical Events. Intravascular Ultrasound Analysis from the Multicenter, Randomized, RAVEL, E-SIRIUS and SIRIUS Trials
  1. Rainer Hoffmann (rhoffmann{at}
  1. University Aachen, Germany
    1. Marie-Claude Morice
    1. Institute Cardiovasculaire Paris-Sud, France
      1. Jeffrey W Moses
      1. Columbia University Medical Center, United States
        1. Peter Fitzgerald
        1. Stanford University, United States
          1. Laura Mauri
          1. Brigham and Women's Hospital, Harvard Medical School, United States
            1. Günther Breithardt
            1. Hospital of the University of Münster, Germany
              1. Joachim Schofer
              1. Center for Cardiology and Vascular Intervention, Hamburg, Germany
                1. Patrick Serruys
                1. Erasmus Medical Center, Netherlands
                  1. Hans-Peter Stoll
                  1. Cordis Clinical Research, Waterloo, Belgium
                    1. Martin Leon
                    1. Columbia University Medical Center, United States


                      Background The impact of incomplete stent apposition (ISA) after drug-eluting stent implantation determined by intravascular ultrasound (IVUS) on late clinical events is not well defined. We sought to evaluate the clinical impact of ISA after sirolimus-eluting stent (SES) placement during a follow-up period of four years.

                      Design Pooled analysis from the RAVEL, the SIRIUS and E-SIRIUS trials, three randomized, multicenter studies comparing SES and BMS.

                      Methods IVUS at angiographic follow-up [at 6 months in RAVEL patients and 8 months in SIRIUS and E-SIRIUS patients] was available in 325 patients (SES: n=180, BMS: n=145). IVUS images were reviewed for the presence of ISA defined as iÝ1 unapposed stent strut. Clinical follow-up was available for a 4-year period in all patients. Frequency, predictors and clinical sequel of ISA at follow-up after SES and BMS implantation were determined.

                      Results ISA at follow-up was more frequent after SES (n=45 [25%]) than after BMS (n= 12 [8.3%], p<0.001). (Canadian Cardiology Society) CCS class III or IV angina at stent implantation (OR=4.69, 95%CI= 2.15-10.23, p<0.001) and absence of diabetes (OR=3.42, 95%CI=1.05-11.1, p=0.041) were predictors of ISA at follow-up after SES placement. Rate of myocardial infarction tended to be slightly higher with ISA compared to non-ISA patients. Considering only SES patients, major adverse cardiac event free survival at four years was identical for those with and without ISA at follow-up (11.1% vs 16.3%, P=0.48).

                      Conclusions ISA at follow-up is more frequent after SES implantation than after BMS implantation. Considering the current very sensitive IVUS definition, ISA appears to be an IVUS finding without significant impact on frequency of major adverse cardiac events even during long-term follow-up.

                      • drugs
                      • intravascular ultrasound
                      • restenosis
                      • stents

                      Statistics from

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                      Linked Articles